What does secondary progressive MS mean?
Secondary-progressive multiple sclerosis (SPMS) is the form of the disease that develops from relapsing-remitting multiple sclerosis (RRMS) . The MS disease course varies across individuals and not all patients who have RRMS will develop SPMS.
What is the difference between fingolimod and siponimod?
Siponimod and fingolimod are S1P receptor modulators that are approved for the treatment of multiple sclerosis (MS). While fingolimod showed benefits only in relapsing MS, siponimod reduced disability progression in secondary progressive MS (SPMS).
Does everyone with progressive MS end up in a wheelchair?
No-one one can be certain how your MS will affect you, although most people with MS don’t use a wheelchair. Learning how to deal with unpredictability and being prepared to manage changes will help you take back the control you might feel MS has taken away.
What is the best treatment for secondary progressive MS?
Mitoxantrone is the only approved drug by the US Food and Drug Administration (FDA) for SPMS, PRMS, and worsening RRMS. There is moderate evidence to suggest its efficacy in reducing disability progression and it remains one of the mainstay treatment in SPMS.
What’s the difference between primary and secondary progressive MS?
Many people who are initially diagnosed with relapsing remitting MS find that, over time, their MS changes. They have fewer or no relapses but their disability increases. As this follows an initial (primary) relapsing remitting phase, this is known as secondary progressive MS.
How fast is progressive MS?
The authors also found that the time it takes to reach 8.0 can vary, but on average, this takes about 20.7 years. Symptom progression is faster in people with PPMS than in those with a relapsing type of MS.
Is Siponimod approved for secondary progressive multiple sclerosis (SPMS)?
Oral siponimod (Mayzent ® ), a next-generation, selective sphingosine 1-phosphate receptor (S1PR) 1 and 5 modulator, is approved in several countries for the treatment of secondary progressive multiple sclerosis (SPMS), with specific indications varying between individual countries.
Does Siponimod (baf312) prevent synaptic neurodegeneration in experimental multiple sclerosis?
Gentile A, Musella A, Bullitta S, et al. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation. 2016; 13 (1):207. doi: 10.1186/s12974-016-0686-4.
Does Siponimod reduce the risk of disability progression?
Interpretation: Siponimod reduced the risk of disability progression with a safety profile similar to that of other S1P modulators and is likely to be a useful treatment for SPMS. Funding: Novartis Pharma AG. Copyright © 2018 Elsevier Ltd.
How many patients were randomly assigned to the Siponimod trial?
This trial is registered with ClinicalTrials.gov, number NCT01665144. Findings: 1651 patients were randomly assigned between Feb 5, 2013, and June 2, 2015 (1105 to the siponimod group, and 546 to the placebo group).